Julie N Leal1, Alexsander K Bressan2, Neeta Vachharajani3, Mithat Gonen4, T Peter Kingham1, Michael I D'Angelica1, Peter J Allen1, Ronald P DeMatteo1, Majella B M Doyle3, Oliver F Bathe2, Paul D Greig5, Alice Wei6, William C Chapman3, Elijah Dixon2, William R Jarnagin7. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Surgery, University of Calgary and Foothills Medical Center, Calgary, Alberta, Canada. 3. Department of Surgery, Washington University in St Louis, St Louis, MO. 4. Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Surgery, Hepatobiliary and Pancreatic Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. 6. Department of Surgery, Hepatobiliary and Pancreatic Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada. 7. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: jarnagiw@mskcc.org.
Abstract
BACKGROUND: Resection of colorectal liver metastases (CRLM) is associated with improved survival; however, the impact of time to resection on survival is unknown. The current multi-institutional study sought to evaluate the influence of time from diagnosis (Dx) to resection (Rx) on survival outcomes among patients with resectable, metachronous CRLM and to compare practice patterns across hospitals. STUDY DESIGN: Medical records of patients with ≤4 metachronous CRLM treated with surgery were reviewed and analyzed retrospectively. Time from Dx to Rx was analyzed as a continuous variable and also dichotomized into 2 groups (group 1: Dx to Rx <3 months and group 2: Dx to Rx ≥3 months) for additional analysis. Survival time distributions after resection were estimated using the Kaplan-Meier method. Between-group univariate comparisons were based on the log-rank test and multivariable analysis was done using Cox proportional hazards model. RESULTS: From 2000 to 2010, six hundred and twenty-six patients were identified. Type of initial referral (p < 0.0001) and use of neoadjuvant (p = 0.04) and/or adjuvant (p < 0.0001) chemotherapy were significantly different among hospitals. Patients treated with neoadjuvant chemotherapy (n = 108) and those with unresectable disease at laparotomy (n = 5) were excluded from final evaluation. Median overall survival and recurrence-free survival were 74 months (range 63.8 to 84.2 months) and 29 months (range 23.9 to 34.1 months), respectively. For the entire cohort, longer time from Dx to Rx was independently associated with shorter overall survival (hazard ratio = 1.12; 95% CI, 1.06-1.18; p < 0.0001), but not recurrence-free survival. Median overall survival for group 1 was 76 months (range 62.0 to 89.2 months) vs 58 months (range 34.3 to 81.7 months) in group 2 (p = 0.10). Among patients with available data pertaining to adjuvant chemotherapy (N = 457; 318 treated and 139 untreated), overall survival (87 months [range 71.2 to 102.8 months] vs 48 months [range 25.3 to 70.7 months]; p <0.0001), and recurrence-free survival (33 months [range 25.3 to 40.7 months] vs 22 months [range 14.5 to 29.5 months]; p = 0.05) were improved significantly. CONCLUSIONS: In select patients undergoing initial resection for CRLM, longer time from Dx to Rx is independently associated with worse overall survival. In addition, despite uniform disease characteristics, practice patterns related to definitely resectable CRLM vary significantly across hospitals.
BACKGROUND: Resection of colorectal liver metastases (CRLM) is associated with improved survival; however, the impact of time to resection on survival is unknown. The current multi-institutional study sought to evaluate the influence of time from diagnosis (Dx) to resection (Rx) on survival outcomes among patients with resectable, metachronous CRLM and to compare practice patterns across hospitals. STUDY DESIGN: Medical records of patients with ≤4 metachronous CRLM treated with surgery were reviewed and analyzed retrospectively. Time from Dx to Rx was analyzed as a continuous variable and also dichotomized into 2 groups (group 1: Dx to Rx <3 months and group 2: Dx to Rx ≥3 months) for additional analysis. Survival time distributions after resection were estimated using the Kaplan-Meier method. Between-group univariate comparisons were based on the log-rank test and multivariable analysis was done using Cox proportional hazards model. RESULTS: From 2000 to 2010, six hundred and twenty-six patients were identified. Type of initial referral (p < 0.0001) and use of neoadjuvant (p = 0.04) and/or adjuvant (p < 0.0001) chemotherapy were significantly different among hospitals. Patients treated with neoadjuvant chemotherapy (n = 108) and those with unresectable disease at laparotomy (n = 5) were excluded from final evaluation. Median overall survival and recurrence-free survival were 74 months (range 63.8 to 84.2 months) and 29 months (range 23.9 to 34.1 months), respectively. For the entire cohort, longer time from Dx to Rx was independently associated with shorter overall survival (hazard ratio = 1.12; 95% CI, 1.06-1.18; p < 0.0001), but not recurrence-free survival. Median overall survival for group 1 was 76 months (range 62.0 to 89.2 months) vs 58 months (range 34.3 to 81.7 months) in group 2 (p = 0.10). Among patients with available data pertaining to adjuvant chemotherapy (N = 457; 318 treated and 139 untreated), overall survival (87 months [range 71.2 to 102.8 months] vs 48 months [range 25.3 to 70.7 months]; p <0.0001), and recurrence-free survival (33 months [range 25.3 to 40.7 months] vs 22 months [range 14.5 to 29.5 months]; p = 0.05) were improved significantly. CONCLUSIONS: In select patients undergoing initial resection for CRLM, longer time from Dx to Rx is independently associated with worse overall survival. In addition, despite uniform disease characteristics, practice patterns related to definitely resectable CRLM vary significantly across hospitals.
Authors: Hugo Pinto Marques; Eduardo Barroso; Mechteld C de Jong; Michael A Choti; Vasco Ribeiro; Ana Marta Nobre; Carlos Carvalho; Timothy M Pawlik Journal: J Surg Oncol Date: 2011-11-07 Impact factor: 3.454
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: G Biasco; E Derenzini; Gl Grazi; G Ercolani; M Ravaioli; M A Pantaleo; G Brandi Journal: Cancer Treat Rev Date: 2006-03-20 Impact factor: 12.111
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321
Authors: Jean-Michel Aubin; Alexsander K Bressan; Sean C Grondin; Elijah Dixon; Anthony R MacLean; Sean Gregg; Patricia Tang; Gilaad G Kaplan; Guillaume Martel; Chad G Ball Journal: Can J Surg Date: 2018-08 Impact factor: 2.089
Authors: G Paul Wright; Katherine E Poruk; Mazen S Zenati; Jennifer Steve; Nathan Bahary; Melissa E Hogg; Amer H Zuriekat; Christopher L Wolfgang; Herbert J Zeh; Matthew J Weiss Journal: J Gastrointest Surg Date: 2016-09-07 Impact factor: 3.452
Authors: S Bennett; K Søreide; S Gholami; P Pessaux; C Teh; E Segelov; H Kennecke; H Prenen; S Myrehaug; D Callegaro; J Hallet Journal: Curr Oncol Date: 2020-10-01 Impact factor: 3.677
Authors: Jean-Michel Aubin; Alexsander K Bressan; Sean C Grondin; Elijah Dixon; Anthony R MacLean; Sean Gregg; Patricia Tang; Gilaad G Kaplan; Guillaume Martel; Chad G Ball Journal: Can J Surg Date: 2018-06-01 Impact factor: 2.089
Authors: Andre Gorgen; Hala Muaddi; Wei Zhang; Ian McGilvray; Steven Gallinger; Gonzalo Sapisochin Journal: Can J Gastroenterol Hepatol Date: 2018-01-10
Authors: Sebastian Stintzing; Jobst von Einem; Christoph Fueweger; Alfred Haidenberger; Michael Fedorov; Alexander Muavcevic Journal: Cancer Res Treat Date: 2018-04-16 Impact factor: 4.679
Authors: Paolo Magistri; Cecilia Battistelli; Gabriele Toietta; Raffaele Strippoli; Andrea Sagnotta; Antonello Forgione; Fabrizio Di Benedetto; Stefania Uccini; Paola Vittorioso; Francesco D'Angelo; Paolo Aurello; Giovanni Ramacciato; Giuseppe Nigri Journal: J Microsc Ultrastruct Date: 2019 Jul-Sep